Depatux-M fails to meet primary endpoint in late-stage trial for newly diagnosed glioblastoma

Written by Sharon Salt, Editor

AbbVie (IL, USA) has announced that it halted enrolment in all studies of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) after an interim analysis of a Phase III trial (INTELLANCE-1) demonstrated that the drug failed to prolong overall survival compared to placebo in individuals with newly diagnosed glioblastoma whose tumors have EGFR amplification. An Independent Data Monitoring committee recommended the study be stopped due to lack of survival benefit for patients receiving Depatux-M compared with placebo when added to the standard regimen of radiation and temozolomide. The randomized, placebo-controlled Phase III study was designed to evaluate the efficacy and safety...

To view the full article, please register now for access

It's completely free